[go: up one dir, main page]

MX2012014163A - Uso de acido sialico, precursor de acido sialico o una combinacion de los anteriores para preparar medicamentos utiles en una condicion diabetica o sindrome nefrotico. - Google Patents

Uso de acido sialico, precursor de acido sialico o una combinacion de los anteriores para preparar medicamentos utiles en una condicion diabetica o sindrome nefrotico.

Info

Publication number
MX2012014163A
MX2012014163A MX2012014163A MX2012014163A MX2012014163A MX 2012014163 A MX2012014163 A MX 2012014163A MX 2012014163 A MX2012014163 A MX 2012014163A MX 2012014163 A MX2012014163 A MX 2012014163A MX 2012014163 A MX2012014163 A MX 2012014163A
Authority
MX
Mexico
Prior art keywords
nephrotic syndrome
methods
present disclosure
provides
proteinuria
Prior art date
Application number
MX2012014163A
Other languages
English (en)
Other versions
MX359930B (es
Inventor
Sumant Chugh
Original Assignee
Sumant Chugh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumant Chugh filed Critical Sumant Chugh
Publication of MX2012014163A publication Critical patent/MX2012014163A/es
Publication of MX359930B publication Critical patent/MX359930B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción provee una base bioquímica de síndrome nefrótico y provee una explicación para la proteinuria observada y otros efectos; como resultado, la presente descripción provee un método para tratar y/o prevenir el síndrome nefrótico así como métodos para aliviar síntomas asociados con el síndrome nefrótico; la presente descripción provee además métodos para reducir la proteinuria en síndrome nefrótico y otros estados de enfermedad que se discuten en la presente.
MX2012014163A 2010-06-05 2011-06-03 Uso de ácido siálico, precursor de ácido siálico o una combinación de los anteriores para preparar medicamentos útiles en una condición diabética o síndrome nefrótico. MX359930B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35186510P 2010-06-05 2010-06-05
US13/152,169 US20110301103A1 (en) 2010-06-05 2011-06-02 Methods of Treatment
PCT/US2011/039058 WO2011153429A2 (en) 2010-06-05 2011-06-03 Methods of treatment

Publications (2)

Publication Number Publication Date
MX2012014163A true MX2012014163A (es) 2013-05-17
MX359930B MX359930B (es) 2018-10-16

Family

ID=45064913

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014807A MX373643B (es) 2010-06-05 2011-06-03 Uso de acido sialico, precursor de acido sialico o una combinacion de los anteriores para preparar medicamentos utiles en una condicion diabetica o sindrome nefrotico.
MX2012014163A MX359930B (es) 2010-06-05 2011-06-03 Uso de ácido siálico, precursor de ácido siálico o una combinación de los anteriores para preparar medicamentos útiles en una condición diabética o síndrome nefrótico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017014807A MX373643B (es) 2010-06-05 2011-06-03 Uso de acido sialico, precursor de acido sialico o una combinacion de los anteriores para preparar medicamentos utiles en una condicion diabetica o sindrome nefrotico.

Country Status (10)

Country Link
US (3) US20110301103A1 (es)
EP (1) EP2575805A4 (es)
JP (1) JP2013533857A (es)
KR (2) KR20130132723A (es)
CN (1) CN103153301A (es)
AU (2) AU2011261268B2 (es)
CA (2) CA2801770C (es)
IL (2) IL223434A (es)
MX (2) MX373643B (es)
WO (1) WO2011153429A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2680842C (en) 2007-05-31 2015-11-24 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health N-acetyl mannosamine or derivatives thereof for use in treating a kidney disorder in a mammal
US9139629B2 (en) 2010-06-05 2015-09-22 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
JP2016516726A (ja) * 2013-03-15 2016-06-09 ザ・ユー・エイ・ビー・リサーチ・フアンデーシヨン ネフローゼ症候群及び関連状態の治療方法
CA2979640A1 (en) 2015-02-25 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sialylation-increasing therapies for diseases associated with oxidative stress
US20180085385A1 (en) * 2015-04-03 2018-03-29 The University Of Tokyo Glucose-sensitive cell protecting agent
US20230393147A1 (en) * 2020-10-22 2023-12-07 The Brigham And Women’S Hospital, Inc. Methods for identifying and treating antibody-mediated acquired primary or recurrent idiopathic nephrotic syndrome
CN116558929B (zh) * 2023-07-07 2023-09-19 中日友好医院(中日友好临床医学研究所) 一种足细胞免疫荧光染色的方法及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04112829A (ja) * 1990-08-30 1992-04-14 Mect Corp 腎疾患治療薬
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6274568B1 (en) * 1998-08-06 2001-08-14 Ronald L. Schnaar Compounds for altering cell surface sialic acids and methods of use therefor
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
EP2013224A2 (en) * 2006-04-27 2009-01-14 Syddansk Universitet Methods for isolation and analysis of sialylated and phosphorylated peptides
JP4005115B1 (ja) * 2007-02-08 2007-11-07 日本臓器製薬株式会社 疼痛疾患治療剤
CA2680842C (en) 2007-05-31 2015-11-24 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health N-acetyl mannosamine or derivatives thereof for use in treating a kidney disorder in a mammal
WO2009006591A1 (en) * 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Inhibitors of polysialic acid de-n-acetylase and methods for using the same
WO2009020641A1 (en) * 2007-08-08 2009-02-12 The Johns Hopkins University Hybrid scfa-hydroxyl-derivatized monosaccharides, methods of synthesis, and methods of treating disorders
WO2010027028A1 (ja) * 2008-09-04 2010-03-11 国立大学法人 東京大学 脳機能低下の改善剤
WO2010131712A1 (ja) * 2009-05-15 2010-11-18 財団法人ヒューマンサイエンス振興財団 Ｇｎｅタンパク質の機能低下に起因する疾患の治療用医薬剤、食品組成物、食品添加物
JP5904560B2 (ja) 2010-06-05 2016-04-13 ザ ユーエイビー リサーチ ファウンデーションＴｈｅ ＵＡＢ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ ネフローゼ症候群および関連容態の治療のための方法

Also Published As

Publication number Publication date
KR20180009382A (ko) 2018-01-26
AU2017200933B2 (en) 2019-02-21
IL223434A (en) 2017-12-31
IL256026A (en) 2018-01-31
KR20130132723A (ko) 2013-12-05
WO2011153429A9 (en) 2012-05-18
CA2801770A1 (en) 2011-12-08
US20110301103A1 (en) 2011-12-08
WO2011153429A2 (en) 2011-12-08
US20160256478A1 (en) 2016-09-08
MX373643B (es) 2020-05-04
JP2013533857A (ja) 2013-08-29
AU2017200933A1 (en) 2017-03-02
MX359930B (es) 2018-10-16
US9827259B2 (en) 2017-11-28
EP2575805A2 (en) 2013-04-10
EP2575805A4 (en) 2013-12-11
CA3066017A1 (en) 2011-12-08
AU2011261268B2 (en) 2016-11-10
US10624914B2 (en) 2020-04-21
CA3066017C (en) 2023-01-10
CA2801770C (en) 2020-03-10
US20180055865A1 (en) 2018-03-01
AU2011261268A1 (en) 2013-01-24
CN103153301A (zh) 2013-06-12
IL256026B (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
PH12013502487A1 (en) Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
AU2011328009A8 (en) Compounds and methods for treating pain
WO2009109911A8 (en) Methods of treating chronic pain
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
WO2012092336A3 (en) Molecular profiling for cancer
WO2012129084A3 (en) Glucosylceramide synthase inhibitors
WO2013006490A3 (en) Antibodies that specifically bind to tim3
EP3489360A3 (en) Modulation of nuclear-retained rna
MX373643B (es) Uso de acido sialico, precursor de acido sialico o una combinacion de los anteriores para preparar medicamentos utiles en una condicion diabetica o sindrome nefrotico.
WO2012106735A3 (en) Plasma-assisted skin treatment
MY172372A (en) Compositions and methods for lowering triglycerides
WO2011161695A8 (en) Sinergistic composition of microbes, enzymes and cofactors for rapid treatment of wastewater and process therefor
HK1198689A1 (en) Antibody formulations and methods
WO2012116010A3 (en) Antibiotic tolerance inhibitors
WO2012158672A3 (en) Compounds for use in treatment of mucositis
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
WO2010005565A3 (en) Method of treating glycogen storage disease
AP2012006124A0 (en) Methods and compositions for treating thyroid-related medical conditions with reduced folates.
IN2012DN01414A (es)
MX358879B (es) Composiciones y métodos para el tratamiento de alquitrán de la perforación de pozo.
WO2011041325A3 (en) Methods and compositions for the treatment of viral disorders
WO2011019867A3 (en) Dietary supplements and methods for treating pain and inflammation

Legal Events

Date Code Title Description
FG Grant or registration